Clinical trials: Invasive Pulmonary Aspergillosis
Respiratory Infection, Invasive Pulmonary Aspergillosis
Early Diagnosis of Invasive Lung Aspergillosis
The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in…
- Trial name
- NCT05860387
- Testing
- Next generation improvement of early invasive aspergillosis
- Where
- 7 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Liver Cirrhosis, Viral Pneumonia
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species.
- Conditions
- Liver Cirrhosis, Viral Pneumonia, Fungal Infection, Invasive Pulmonary Aspergillosis
- Trial name
- LIVERIPA (NCT07238114)
- Where
- Belgium
- Volunteers
- 450 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Invasive Fungal Infection
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
Multiple factors are associated with a large variability in voriconazole exposure following standard dose administration, such as non-linear saturable pharmacokinetics, drug-drug interactions, liver disease, patient age, and…
- Trial name
- NCT01148160
- Testing
- voriconazole
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Asan Medical Center
Invasive Pulmonary Aspergillosis, Breath Samples
VOC in Breath Samples for the Diagnosis of IPA
The diagnosis of invasive pulmonary aspergillosis (IPA) bears grave implications for the prognosis and treatment plan of the immunosuppressed patient.
- Conditions
- Invasive Pulmonary Aspergillosis, Breath Samples, Volatile Organic Compounds
- Trial name
- NCT05982912
- Testing
- breath sampling
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Invasive Pulmonary Aspergillosis
PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value
Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk patients not receiving antifungal prophylaxis.
- Trial name
- ASP (NCT07313527)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Invasive Pulmonary Aspergillosis
Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid
The aim of this research project is to compare the results of Aspergillus specific test methods Aspergillus Galactomannan Enzyme Immunoassay (GM-EIA), Aspergillus polymerase chain reaction (PCR), Aspergillus Galactomannan Lateral…
- Trial name
- DipA2 (NCT04848831)
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Invasive Aspergillosis, Pleural Effusion
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Diagnostic accuracy of biomarker testing (galactomannan (GM), (1
- Conditions
- Invasive Aspergillosis, Pleural Effusion, Immunosuppression
- Trial name
- EFFU-ASP (NCT02104479)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Heidelberg University
Aspergillosis; Pulmonary, Invasive (Etiology)
Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients
The objective of this study is to deliver proof of concept that antifungal prophylaxis can reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit) patients with severe influenza.
- Trial name
- POSA-FLU (NCT03378479)
- Testing
- SOC +Posaconazole 18 MG/ML (milligram/milliliter), standard of care (SOC)
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 88 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Acute Myeloid Leukemia, Allogeneic Haematopoietic Progenitor Cell Transplant
Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis
The trial is planned as a multicentric, national, phase II, open-label trial to evaluate safety and tolerance of nebulized Liposomal Amphotericin B (Ambisome) for LMA patients during the induction therapy ,intensification, plus…
- Trial name
- AMBINEB (NCT00391014)
- Testing
- liposomal Amphotericine B
- Where
- 4 sites in Spain
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Invasive Aspergillosis, Antifungal Therapy
Treatment Duration of IPA
The goal of this observational study is to identify the duration of posaconazole-initiated antifungal treatment for IPA in patients with hematological malignancies and to explore the value of monitoring immune factors and cells…
- Trial name
- NCT06583512
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University People's Hospital
Invasive Pulmonary Aspergillosis
Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
Background Invasive pulmonary aspergillosis (IPA) remains an important cause of morbidity and mortality among patients with hemato-oncological malignancies.
- Trial name
- NCT02058316
- Testing
- Lateral Flow Device Test
- Where
- 4 sites in Austria, Germany
- Volunteers
- 350 people
- Sponsor
- Medical University of Graz
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Pulmonary Aspergillosis, Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.
- Trial name
- NCT01499433
- Testing
- caspofungin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Invasive Pulmonary Aspergillosis
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
- Trial name
- SCYNERGIA (NCT03672292)
- Testing
- SCY-078, Voriconazole
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 22 people
- Sponsor
- Scynexis, Inc.
Survival After IPA, Risk Factors for IPA
Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients
Invasive pulmonary aspergillosis (IPA) is difficult to diagnose and remains a cause of high morbidity and mortality in critically ill patients in the ICU.
- Trial name
- DipA (NCT01866020)
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bronchoalveolar Lavage Fluid, Lung Infection
Diagnosis of Lung Complication After Allo-HSCT by Multiple Parameter System Through BAL
The aim of this study was to evaluate the diagnostic yield for lung complication after allo-HSCT by multiple parameter system through BAL.
- Trial name
- SHSYXY-BAL (NCT04051372)
- Testing
- Bronchoscopic Alveolar Lavage
- Volunteers
- 250 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Covid19, Aspergillosis
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections.
- Conditions
- Covid19, Aspergillosis, Fungal Infection
- Trial name
- CAPA IFI (NCT04818853)
- Testing
- Observation to monitor patients for these infections
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- University of Alabama at Birmingham
Influenza With Pneumonia, Pulmonary Aspergillosis
Prospective Observational Trial of IAPA
A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU…
- Trial name
- IAPAFLU (NCT04530799)
- Testing
- Identification of biomarkers for IAPA via patient sampling
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 241 people
- Sponsor
- Radboud University Medical Center
Aspergillosis
Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis
A Phase II/III randomized double-blind study comparing the safety and the efficacy of a weekly administration of 25 mg nebulized AmBisome with nebulized placebo solution to prevent invasive pulmonary aspergillosis in neutropenic…
- Trial name
- NCT00263315
- Testing
- nebulised liposomal amphotericin B
- Where
- 2 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center
Bronchoalveolar Lavage Fluid, Sensitivity and Specificity
Aspergillosis Detection Via EBC-GM in Ventilated Patients
Brief Research Proposal: Non-Invasive Detection of Invasive Pulmonary Aspergillosis in ICU Patients Background: Invasive Pulmonary Aspergillosis (IPA) is a critical threat to patients in ICUs, especially those undergoing…
- Conditions
- Bronchoalveolar Lavage Fluid, Sensitivity and Specificity, Critical Illness, Respiration Failure
- Trial name
- NCT06333379
- Testing
- Compare the levels of Galactomannan (GM) levels in exhaled breath condensate (EBC) and BALF
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lin Chen